secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2024-06-25T23:59:59+00:00
Accession:  0001628280-24-029936
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ChromaDex CFO Brianna Gerber resigns effective July 12; consulting transition through Aug 12
--------------------------------------------------------------------------------

- CFO & CAO Brianna Gerber resigns effective July 12, 2024; company beginning search for replacement.
- Post-resignation consulting agreement through Aug 12, 2024; $1,000 consulting fee.
- Outstanding stock options and RSUs continue to vest during consulting period per existing equity plan terms.
- Gerber confirms resignation is without Good Reason; no severance benefits under employment agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000162828024029936/0001628280-24-029936-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000162828024029936/cdxc-20240619.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-029936

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer